Mesoblast reports $115 million Ryoncil revenue
Mesoblast (NASDAQ:MESO) reported preliminary net revenue of US$115 million from Ryoncil for the full year ended June 30, 2026, including US$36 million in the fourth quarter, as the company continues commercial expansion of the therapy.



_1436940_640x360_2506167363818-640x360.webp&w=3840&q=75)

-640x360.webp&w=3840&q=75)

_1436926_640x360_2506159683581-640x360.webp&w=3840&q=75)
_1436900_640x360_2506155587712-640x360.webp&w=3840&q=75)

_1436890_640x360_2506148931945-640x360.webp&w=3840&q=75)
_1436880_640x360_2506150467772-640x360.webp&w=3840&q=75)